Close Menu

Jane Pine Wood

Sep 15, 2016

OPKO Health has appointed Jane Pine Wood as chief legal and compliance officer of its wholly owned subsidiary, BioReference Laboratories. Wood comes to OPKO Health from the multistate law firm McDonald Hopkins, where she served as a member of the firm's board of directors. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories. Wood is also a frequent speaker at national and state laboratory and pathology meetings and a contributor to association publications.

More Like This

Nov 11, 2019

LetsGetChecked: Troy Cox

LetsGetChecked appointed Troy Cox to its board. He has more than 30 years of expereience in healthcare, most recently as president and CEO of Foundation Medicine, now part of Roche. Prior to that, he was senior vice president and an officer at Genentech. He joined the board of Sophia Genetics in July.

Nov 07, 2019

Glympse Bio: Tracey Dawson

Glympse Bio, a firm developing non-invasive disease detection and monitoring technology, has named Tracey Dawson as chief commercial officer and head of strategy. Dawson joins Glympse from Biogen, where she was VP of global product development and commercialization for the multiple sclerosis franchise. Prior to that she was group vice president and head of the US genetic disease franchise for Shire. She has also worked for Genentech and Eli Lilly, and holds a PhD in physical organic chemistry from the University of Hull.

Nov 07, 2019

Epify: Leander Van Neste

Epify, a company developing epigenetic biomarkers for cancer diagnosis, has appointed Leander Van Neste as chief scientific officer. Van Neste joins Epify from miDiagnostics, where he served as vice president of scientific and clinical affairs. He has also served as vice president of clinical and scientific affairs for MDxHealth. Van Neste also simultaneously held academic appointments, including as a professor at Ghent University from 2015 to 2018, and an assistant professor at Universiteit Maastricht from 2013 to 2016. Prior to this he was a visiting research associate at Johns Hopkins School of Medicine.

Nov 06, 2019

LabCorp: Brian Caveney, Mark Schroeder, John Ratliff

Laboratory Corporation of America has named Brian Caveney executive vice president and president of Diagnostics, and Mark Schroeder executive vice president and president of Diagnostics laboratory operations and global supply chain. Also, John Ratliff, CEO of LabCorp's Covance business, is leaving the company to pursue another opportunity. The changes took effect immediately. 

Caveney joined LabCorp as CMO in 2017. Before that he was CMO of Blue Cross Blue Shield of North Carolina. Schroeder has been with LabCorp since 2007 and assumed the role of enterprise-wide chief supply chain officer in 2016. 


Nov 05, 2019

Congenica: Heiner Dreismann

Heiner Dreismann has been appointed as a non-executive director and senior independent director of UK genome analysis firm Congenica. Previously, he was president and CEO of Roche Molecular Systems. He was also head of global business development at Roche Diagnostics and a member of Roche's global diagnostics executive committee. Since leaving Roche, he has been on the board of biotechnology and healthcare companies in the US, Europe, and Israel.

Nov 05, 2019

Accelerate Diagnostics: Roland Diggelmann

Roland Diggelmann has been appointed to Accelerate Diagnostics' board of directors. Diggelmann is currently CEO of Smith+Nephew, a British medical equipment manufacturing company, having recently succeeded Namal Nawana, the former CEO of Alere. Diggelmann previously served as CEO of Roche Diagnostics, and also worked in the orthopedics sector at Sulzer Orthopedics and Zimmer Group. 

Nov 05, 2019

Section 32: Steven Kafka

Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.

Nov 05, 2019

Biodesix: Scott Hutton, David Brunel

Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.

Hutton is currently Biodesix's COO and has more than 20 years of experience in the medical device, medical technology, and diagnostics industries. Prior to joining Biodesix, he was senior vice president and general manager of vascular interventions at Spectranetics, and VP, GM of neurosurgery at Medtronic. 

Nov 05, 2019

PredictImmune: Steven Martin

Cambridge, UK-based PredictImmune has appointed Steven Martin to its board. Martin is currently the managing partner of Paxton Advisors, an advisory and consulting firm based in Omaha, Nebraska. He was previously the president and CEO of Blue Cross and Blue Shield of Nebraska, and also belonged to the company's board of directors from 2002 to 2018. Martin was the founding board chair of Think Whole Person Healthcare, a primary care clinic and pharmacy in Nebraska. 

Nov 01, 2019

FDA: Stephen Hahn

Stephen Hahn is expected to be nominated as commissioner of the US Food and Drug Administration by President Trump, the White House said on Nov. 1. Hahn has been the chief medical executive at the MD Anderson Cancer Center since 2018 and a professor of radiation oncology at MD Anderson since 2015. Previously, he was chair of the Department of Radiation Oncology at the University of Pennsylvania, and before that, he was a senior investigator at the National Cancer Institute. Hahn holds a medical degree from Temple University and a BA in biology from Rice University. Following his appointment, Ned Sharpless, current acting commissioner of the FDA, will return to his post as director of the NCI, and Doug Lowy, who took over for Sharpless, will return to be principal deputy director of the NCI.

Oct 31, 2019

NanoString: Don Kania

NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.

Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.

Oct 29, 2019

Atmo Biosciences: Chris Roberts

Chris Roberts has joined the board of Atmo Biosciences as a non-executive director. The Melbourne, Australia-based company is developing an ingestible gas-sensing capsule that can profile gases with the gut for better diagnosis and treatment of gastrointestinal disorders. Robers has more than 40 years of experience in the international medical device business, including as CEO of Cochlear and founding director and executive vice president of ResMed. Since retiring from Cochlear, he has been chairman of OncoSil Medical, as well as non-executive director of Clarity Pharmaceuticals and o'connell Street Associates. 

Oct 29, 2019

MeMed: Frédéric Sweeney

Frédéric Sweeney has joined MeMed as its chief business development officer. He will focus on building strategic partnerships to accelerate market access to the company's technologies, which include the MeMed BV, an immune system, blood-based test that distinguishes bacterial from viral infections, and the MeMed Key platform for measuring multiple proteins with central lab precision at the point of care within minutes. Sweeney was most recently entrepreneur-in-residence at Versant Ventures, and chief buisness officer at Northern Biologics. Prior to that, he was vice president of corporate development and head of strategic financing at BioMérieux. He was head of business development and strategy at T2 Biosystems before that. 

Oct 28, 2019

Roche: Matthew Sause

Roche Diagnostics has named Matthew Sause as president and CEO, North America, effective Nov. 4. He replaces Jack Phillips, who left Roche at the end of August. Sause was previously the senior VP and head of global commercial product strategy at Gilead Sciences. From 2002 to 2014, Sause worked in the diagnostics division at Roche, filling US-based sales roles in molecular diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In 2014, Sause moved to the pharmaceuticals division, where he was president of country operations in Peru and South Korea, before becoming VP and lifecycle leader for Roche's cancer drug Tecentriq.  

Oct 23, 2019

Laboratory for Advanced Medicine: Alan List

Laboratory for Advanced Medicine has appointed Alan List to its board of directors. A practicing oncologist, List currently serves as president and CEO of the Moffitt Cancer Center in Tampa, Florida. Previously he filled various other roles at Moffitt, including, most recently, executive VP and physician-in-chief. List is an active member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. He earned his medical degree from the University of Pennsylvania.